Results 151 to 160 of about 14,159 (238)

Identification of BCL11A, NTN5, and OGN as Diagnosis Biomarker of Papillary Renal Cell Carcinomas by Bioinformatic Analysis. [PDF]

J Kidney Cancer VHL
Haghshenas Z, Fathi S, Ahmadzadeh A, Nazari E.   +3 more
europepmc   +1 more source

Open-Label Phase II Trial of First-Line Everolimus Monotherapy in Patients with Advanced Papillary Renal Cell Carcinoma: Raptor Interim Analysis

, 2012
Bernard Escudier, Sergio Bracarda, Pablo Maroto, Cezary Szczylik, Paul Nathan, S. Négrier, K. Slimane, Christoph May, Camillo Porta, Viktor Grünwald   +9 more
openalex   +1 more source

First Line Sunitinib in Type I and II Papillary Renal Cell Carcinoma (PRCC): Supap- A Phase II Study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase Trials (GEP)

, 2012
Alain Ravaud, Stéphane Oudard, Marc de Fromont, Christine Chevreau, Gwénaëlle Gravis, Sylvie Zanetta, Christine Théodore, Marta Jimenez, Emmanuel Sevin, Bernard Escudier   +9 more
openalex   +1 more source

Early-stage clear cell tubulopapillary renal cell carcinoma: imaging features and distinction from clear cell and papillary subtypes [PDF]

, 2016
Gevork N. Mnatzakanian, Atul B. Shinagare, V. Anik Sahni, Michelle S. Hirsch, Stuart G. Silverman   +4 more
openalex   +1 more source

Coexisting papillary thyroid carcinoma and renal cell carcinoma: 4 cases [PDF]

, 2016
Mehmet Çelik, Semra Aytürk, Bulbul Buket Yilmaz, Nuray Can, Ebru Taştekin, Atakan Sezer, Funda Üstün, Sibel Güldiken   +7 more
openalex   +1 more source

The impact of the new WHO classification of renal cell carcinoma on the diagnosis of hereditary leiomyomatosis and renal cell carcinoma. [PDF]

Nephrol Dial Transplant
Degenhardt J, Tolkach Y, Amin MB, Mosiello G, Ertoy Baydar D, Cornec-Le Gall E, DiCola J, Elhag D, Frezza C, Halbritter J, Blanco I, Jewett MAS, Lattouf JB, Lovitt G, Lundgren PO, Maher ER, Mulders P, Shuch B, Hartmann A, Müller RU.   +19 more
europepmc   +1 more source

Papillary renal cell carcinoma (pathology)

, 2014
Francis Fortin, Andrew M. Ryan
openalex   +1 more source

High mobility group protein 2 (HMGA2) is highly expressed in a broad range of benign and malignant tumors. [PDF]

Virchows Arch
Chirico V, Ergüven FB, Möller K, Lutz F, Viehweger F, Kluth M, Hube-Magg C, Bernreuther C, Sauter G, Marx AH, Simon R, Jacobsen F, Lebok P, Clauditz TS, Wilczak W, Freytag M, Reiswich V, Dum D, Hinsch A, Kind S, Luebke AM, Schlichter R, Weidemann S, Krech T, Steurer S, Fraune C, Minner S, Gorbokon N, Lennartz M, Burandt E, Menz A.   +30 more
europepmc   +1 more source

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models

, 2015
Alwin G. Schuller, Evan Barry, Rhys D.O. Jones, Ryan E. Henry, Melanie M. Frigault, Garry Beran, David Linsenmayer, Maureen M. Hattersley, Aaron Smith, Joanne Wilson, Stefano Cairo, Olivier Déas, Delphine Nicolle, Ammar Adam, Michael Zinda, Corinne Reimer, Stephen E. Fawell, Edwin Clark, Celina M. D’Cruz   +18 more
openalex   +1 more source

Patients with Papillary Renal Cancer and Germline Duplication of <i>MET</i> Exons 5-21. [PDF]

Biomedicines
Mikhaylenko DS, Kuryakova NB, Bostanova FM, Zabnenkova VV, Ryzhkova OP, Volodin IV, Zaletaev DV, Pustoshilov DV, Kutsev SI, Strelnikov VV.   +9 more
europepmc   +1 more source